Chemotherapy News and Research

Latest Chemotherapy News and Research

Older patients with acute myeloid leukemia may benefit from decitabine drug

Older patients with acute myeloid leukemia (AML) might benefit from a drug that reactivates genes that cancer cells turn off, according to research at Washington University School of Medicine in St. Louis and collaborating institutions.

12 Jan 2010

Increased doses of erlotinib drug may lead to better outcomes in lung cancer patients

Although erlotinib is an approved second-line therapy for lung cancer, its management is complicated by side effects that get worse as the dose increases.

12 Jan 2010

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

A study recently conducted by US Oncology and Aetna finds that evidence-based care for patients with non-small cell lung cancer (NSCLC) results in an average cost savings of 35 percent over 12 months while demonstrating equivalent health outcomes. The study, which compared patients treated with evidence-based guidelines (also known as ‘on pathway’) to those treated with non-evidence-based guidelines (also known as ‘off pathway’), was published in the peer-reviewed Journal of Oncology Practice.

12 Jan 2010

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has begun enrolling patients in INSPIRE 2, a Phase IIa clinical program evaluating the company’s investigative immune-modulator, recombinant human Interleukin-7 (CYT107), in the treatment of chronically HIV-1 infected patients classified as Immunological Non Responders (INR) after at least 12 months of highly active anti-retroviral therapy (HAART).

12 Jan 2010

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

Human Genome Sciences, Inc. today will announce its priority goals for 2010 and report on the Company’s increasing momentum toward commercialization of late-stage products for systemic lupus and chronic hepatitis C in a presentation by H. Thomas Watkins, President and Chief Executive Officer, to financial analysts and investors at the 28th Annual JPMorgan Healthcare Conference in San Francisco.

12 Jan 2010

CEL-SCI completes validation of its GMP manufacturing facility

CEL-SCI Corporation, a late-stage oncology company and a developer of vaccines and therapeutics for the prevention and treatment of infectious diseases, announced today it has completed the validation of all critical utilities and manufacturing equipment at its GMP manufacturing facility in Maryland.

12 Jan 2010

4SC commences treatment in its resminostat Phase II trial for HL

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, today announced the treatment of the first patient in a Phase II study evaluating resminostat (4SC-201), an oral pan-histone-deacetylase (HDAC) inhibitor in relapsed or refractory Hodgkin's Lymphoma (HL) patients.

12 Jan 2010

Multigene test results impact physicians and patients' decisions on breast cancer therapy

A 21-gene test that predicts whether early stage breast cancer patients will benefit from chemotherapy is having a big impact on treatment decisions by patients and doctors alike.

12 Jan 2010

PDGFR's role in new blood vessel formation may explain cardiovascular side effects

A growth factor that is a common target of cancer drugs also plays an important role in the heart's response to stress, researchers at The University of Texas M. D. Anderson Cancer Center report online this week in the Journal of Clinical Investigation.

12 Jan 2010

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

Sangamo BioSciences, Inc. announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Juvenile Diabetes Research Foundation International (JDRF).

11 Jan 2010

A.P. Pharma regains compliance for continued listing on Nasdaq Capital Market

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that, on January 7, 2010, it received notice from the Nasdaq Stock Market (Nasdaq) confirming that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Listing Rule 5450(a)(1).

11 Jan 2010

A.P. Pharma receives final milestone payment of $2.5M from Paul Capital Healthcare

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced it has received the final milestone payment of $2.5 million from an affiliate of Paul Capital Healthcare.

11 Jan 2010

Research determines and validates the efficacy of T category in IASLC's Staging Manual

Research released in the January 2010 issue of the Journal of Thoracic Oncology sought to determine and validate the efficacy of the recent reclassification of the T category in the IASLC's Staging Manual in Thoracic Oncology.

9 Jan 2010

Cancer Research UK scientists named on New Year's Honours list

Several of Cancer Research UK's scientists have been named on this year's New Year's Honours list, as has the government's National Cancer Director and a long-term supporter of the charity.

9 Jan 2010

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that the 725th event (patient death) has been reached in its pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) studying its lead product, NOV-002, in combination with first-line chemotherapy.

8 Jan 2010

Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study

ACCESS PHARMACEUTICALS, INC., today announced that it has completed enrollment and evaluation of the last additional cohort of patients in the ongoing clinical study of ProLindac as a monotherapy in ovarian cancer patients who have received at least two prior platinum based treatment regimens.

8 Jan 2010

MUHC unveils new Lung Cancer Navigation Program

A diagnosis of lung cancer can come as a hard blow. The disease has one of the highest mortality rates of all cancers and the sheer complexity of therapy - often involving radiation, chemotherapy and surgery - can leave patients feeling confused and isolated. To help these patients navigate through the complicated treatment process and medical appointments, the MUHC has unveiled its new Lung Cancer Navigation Program (LCNP).

8 Jan 2010

Breakthrough findings could lead to new treatments for prostate, brain and skin cancers

Researchers at the Lady Davis Institute for Medical Research of the Jewish General Hospital and McGill University in Montreal have discovered a previously unsuspected link between two different genetic pathways which suppress the growth of cancer tumours.

8 Jan 2010

Pfizer and Debiopharm Group enter into co-development agreement to conduct Phase 3 trial of tremelimumab

Pfizer Inc. (Pfizer) and Debiopharm Group™ (Debiopharm) announced today that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma.

8 Jan 2010

Epigenetic diagnosis and therapies, a new strategy for treating cancer

A tumor's genetic profile is often useful when diagnosing and deciding on treatment for certain cancers, but inexplicably, genetically similar leukemias in different patients do not always respond well to the same therapy.

7 Jan 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Older patients with acute myeloid leukemia may benefit from decitabine drug

Increased doses of erlotinib drug may lead to better outcomes in lung cancer patients

Evidence-based care for lung cancer patients results in an average cost savings of 35%, says study

Cytheris commences enrollment in its recombinant human Interleukin-7 INSPIRE 2 program for HIV

HGS reports commercialization of late-stage products for systemic lupus and chronic hepatitis C

CEL-SCI completes validation of its GMP manufacturing facility

4SC commences treatment in its resminostat Phase II trial for HL

Multigene test results impact physicians and patients' decisions on breast cancer therapy

PDGFR's role in new blood vessel formation may explain cardiovascular side effects

Sangamo BioSciences initiates two new clinical trials of ZFP Therapeutics

A.P. Pharma regains compliance for continued listing on Nasdaq Capital Market

A.P. Pharma receives final milestone payment of $2.5M from Paul Capital Healthcare

Research determines and validates the efficacy of T category in IASLC's Staging Manual

Cancer Research UK scientists named on New Year's Honours list

Novelos Therapeutics to conclude pivotal Phase 3 trial in advanced non-small cell lung cancer

Access Pharmaceuticals completes enrollment for Prolindac monotherapy trail, begins combination study

MUHC unveils new Lung Cancer Navigation Program

Breakthrough findings could lead to new treatments for prostate, brain and skin cancers

Pfizer and Debiopharm Group enter into co-development agreement to conduct Phase 3 trial of tremelimumab

Epigenetic diagnosis and therapies, a new strategy for treating cancer

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in